Health Care/Hospital

2024 ASCO | Mabwell to Present Clinical Data of 9MW2821 in Multiple Advanced Solid Tumor

SHANGHAI, April 25, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with an entire industry chain, announced that the Phase I/II clinical study results of the novel Nectin-4-targeting ADC 9MW2821 for multiple advanced solid tumors will be presented in an ...

2024-04-25 22:00 1610

Hyundai Bioscience's antiviral for Dengue Fever to enter clinical trials in Brazil

* "Aiming to offer a Dengue antiviral treatment course in $100 price range" * Hyundai Bioscience decides to conduct dengue clinical trials in Brazil, which has the largest number of Dengue patients and offers a fast-track approval SEOUL, South Korea, April 25, 2024 /PRNewswire/ -- Hyundai Biosc...

2024-04-25 21:41 1509

On-Device AI Healthcare Company Noul Announces 2 Clinical Performance Studies at Pan-African Malaria Conference

* miLab showed almost equivalent to WHO-certified first-degree microscopy experts: Sensitivity of 94.4%, Specificity of 98.1% * African authority on malaria diagnosis said "miLab is a potential game changer in accelerating access to parasitological confirmation" YONGIN, South Korea, April 25,...

2024-04-25 21:00 1634

Antengene Announces One Oral and Three Poster Presentations at ASCO 2024

* Oral session:ATG-008 (mTORC1/2 Inhibitor) combined with PD-1 antibody in Phase II studies for cervical cancer * Three Poster presentations: Phase I/II studies for ATG-031 (anti-CD24 monoclonal antibody) and ATG-022 (Claudin 18.2 antibody-drug conjugate) and selinexor(XPO1 Inhibitor) SHANGHA...

2024-04-25 20:00 2157

Onconic Therapeutics Receives MFDS Approval for JAQBO, a New Treatment for Gastroesophageal Reflux Disease (GERD)

SEOUL, South Korea, April 25, 2024 /PRNewswire/ -- Onconic Therapeutics, a leading biotechnology company in Korea, today announced that the Ministry of Food and Drug Safety (MFDS) of Korea has approved JAQBO (zastaprazan citrate) for the treatment of erosive gastroesophageal reflux disease (GERD)...

2024-04-25 19:57 2189

Waterdrop Files Annual Report on Form 20-F for Fiscal Year 2023

BEIJING, April 25, 2024 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced that it filed its annual report on Form 20-F for the fiscal year ende...

2024-04-25 18:45 2269

PolyU forms global partnership with ZEISS Vision Care to expand impact and accelerate market penetration of patented myopia control technology

HONG KONG, April 25, 2024 /PRNewswire/ -- The Hong Kong Polytechnic University (PolyU) is partnering with ZEISS Vision Care, one of the world's leading manufacturers of eyeglass lenses and ophthalmic instruments, to expand the global impact and speed up the market penetration of PolyU's proprieta...

2024-04-25 17:23 1763

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

* The only solution for intractable cancer caused by mutations in the p53 gene * Planning clinical trials targeting cancer patients with no available treatment due to p53 gene mutations SEOUL, South Korea, April 25, 2024 /PRNewswire/ -- Hyundai Bioscience announced onApril 25th that its clinica...

2024-04-25 17:11 1366

Bazi Bushen Capsule Became the Representative Drug of Anti-aging Chinese Medicine

SHIJIAZHUANG, China, April 25, 2024 /PRNewswire/ -- On April 21, the 3rd Traditional Chinese Medicine Anti-Aging Conference, hosted by the World Federation of Chinese Medicine Societies, was held inShijiazhuang. Yiling Pharmaceutical'sBazi Bushen capsule, as a representative drug of anti-aging i...

2024-04-25 16:07 1693

GSK Advocates Importance of Adult Immunisation amongst Malaysians

KUALA LUMPUR, Malaysia, April 25, 2024 /PRNewswire/ -- As Malaysia's population shifts towards an ageing demographic, the importance of adult immunisation becomes increasingly apparent. By ensuring that individuals receive necessary vaccinations, adults can remain active, be healthy participants ...

2024-04-25 14:53 2111

PRISM BioLab, enters into a Joint Research and Licensing Agreement with Ono

PRISM BioLab will utilize PepMetics®, innovative small molecules that mimic three-dimensional structures of alpha-helix and beta-turns of peptidesfor drug discoveryagainst oncology target selected by Ono TOKYO, April 25, 2024 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery ...

2024-04-25 14:00 1168

United Imaging Healthcare Strengthens Partnership with MedikaBazaar for Indian Market Leadership

COLOMBO, Sri Lanka, April 25, 2024 /PRNewswire/ -- United Imaging, a global leader in healthcare innovations, recently hosted a meeting with MedikaBazaar in Colombo, Sri Lanka, to strategically reinforce their partnership. With a robust four-year collaboration resulting in over 300 installations a...

2024-04-25 12:14 1837

Innovent to Present Clinical Data of Multiple Novel Molecules at the 2024 ASCO Annual Meeting

SAN FRANCISCO and SUZHOU, China, April 25, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmun...

2024-04-25 10:02 2067

ASCO 2024 | Ascentage Pharma to Present Four Studies, Including an Oral Report Featuring the Latest Data of Olverembatinib in SDH-Deficient GIST

SUZHOU, China and ROCKVILLE, Md., April 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that results from four clinical studies of the co...

2024-04-25 09:02 1587

GenScript Biotech Releases 2023 ESG Report: Deepening Green Development Practices, Constructing Sustainable Future Blueprint

PISCATAWAY, N.J., April 24, 2024 /PRNewswire/ -- Recently, GenScript Biotech Corporation (HK.1548), a world leader in technologies and services for life science R&D and manufacture, released its 2023 Environmental, Social, and Governance (ESG) report. This report showcases the company's dedicated...

2024-04-24 22:31 2416

Breakthrough in Lung Cancer Treatment: Dizal to Unveil Groundbreaking Results of Sunvozertinib for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations at 2024 ASCO Annual Meeting

Topline results from Dizal's global pivotal phase II WU-KONG1 Part B study of sunvozertinib will be showcased in a featured oral presentation at the conference. SHANGHAI, April 24, 2024 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing groundbreaking new med...

2024-04-24 22:10 1772

Future Health highlights greater access to treatment for Mental Health Month

SAN FRANCISCO, April 24, 2024 /PRNewswire/ -- A recent poll has highlighted an alarming trend: a staggering 90% of Americans feel we are in a mental health crisis. While Mental Health Month in May seeks to build ...

2024-04-24 22:00 1353

Meihua International Medical Technologies Co., Ltd. Reports 2023 Financial Year Results

YANGZHOU, China, April 24, 2024 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (Nasdaq: MHUA), a reputable manufacturer and provider of Class I, II, and III disposable medical devices with operating subsidiaries inChina, today reported its financial ...

2024-04-24 19:00 2042

Esaote Group: Shareholders' Meeting approves financial statements as of 31 December 2023

* Consolidated revenues up to €273.2 million (+6.5%), EBITDA stands at  €41.7 million (+24.5%); EBIT up to €13.4 million and net profit up to €6.2 million. * Sales increased in all business lines, especially in the ultrasound segment (+9.7%). Second consecutive record sales year for MRI (+3.3%...

2024-04-24 18:00 2201

CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy

First non-immunosuppressive therapy for the treatment of IgA Nephropathy (IgAN) approved inEurope Conditional marketing authorization is based on statistically significant and clinically meaningful results from the phase-III PROTECT trial ST. GALLEN, Switzerland and SAN DIEGO, April 24, 2024 /PR...

2024-04-24 15:00 2113
1 ... 9899100101102103104 ... 849